SEC Contract Filing

Filing Date: 2017-08-04

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>imgn-20170630ex1017013d0.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--HTML document created with Merrill Bridge 7.2.100.0-->
<!--Created on: 8/4/2017 3:12:09 PM-->
<html>
	<head>
 <title>
 imgn_Ex10-1
 </title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

 <p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">

 <font style="display:inline;font-weight:bold;">Exhibit 10.1</font>

 </p>

 <p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">

 &nbsp;

 </p>

 <p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">

 <font style="display:inline;font-weight:bold;text-decoration:underline;">Execution Copy</font>

 </p>

 <p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

 &nbsp;

 </p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
 <p style="margin:0pt;text-align:center;text-decoration:underline;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;">EXCLUSIVE LICENSE AND ASSET PURCHASE <a name="_9kMHG5YVt3AB7AIR7vuirsuA"></a><a name="_9kMHG5YVt39A7AJS7vuirsuA"></a>AGREEMENT</font>
 </p>
 <p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-weight:bold;">THIS</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;">EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT</font><font style="display:inline;"> (this &#x201C;<a name="_9kR3WTr17858HQ5tsgpqs8"></a><a name="_9kR3WTr19A5EIL5tsgpqs8"></a><a name="_9kR3WTr2445EKN5tsgpqs8"></a></font><font style="display:inline;font-weight:bold;">Agreement</font><font style="display:inline;">&#x201D;) is made effective as of May 23, 2017 (the &#x201C;</font><font style="display:inline;font-weight:bold;">Effective Date</font><font style="display:inline;">&#x201D;) by and between <a name="_9kR3WTr12346DQ6bgu2wit6YUC43Dx4D9F21uE"></a>Debiopharm International, S.A., a <a name="_9kR3WTr6GC6FMhd0x82tvw41mlx8AzyN"></a>Swiss limited company (&#x201C;</font><font style="display:inline;font-weight:bold;">Debiopharm</font><font style="display:inline;">&#x201D;) having a place of business at <a name="_9kR3WTr26668FUI184"></a>Forum &#x201C;apr&#xE8;s-demain,&#x201D; <a name="_9kR3WTr3CB46AM8hnsu"></a><a name="_9kR3WTr266688K8hnsuZLyD4qxC"></a>Chemin Messidor 5-7, <a name="_9kR3WTr266687J1ot"></a>Case Postale 5911, CH-1002 <a name="_9kR3WTr3CB48ATAq9qm0s"></a>Lausanne, Switzerland, and <a name="_9kR3WTr12347FWJu350UFtYTu"></a>ImmunoGen, Inc., a <a name="_9kR3WTr3CB48BVBo7qbj2Ez1HH"></a>Massachusetts corporation (&#x201C;</font><font style="display:inline;font-weight:bold;">ImmunoGen</font><font style="display:inline;">&#x201D;) having a place of business at <a name="_9kR3WTr156469HJCgWu6yxmjF1p5yawGDv1o7mY"></a>830 Winter Street, Waltham, MA 02451-1477, &nbsp;<a name="_9kR3WTr3CB49JkBs"></a>U.S.A.&nbsp;&nbsp;ImmunoGen and Debiopharm are sometimes each hereinafter referred to as a &#x201C;</font><font style="display:inline;font-weight:bold;">Party</font><font style="display:inline;">&#x201D; and collectively as the &#x201C;</font><font style="display:inline;font-weight:bold;">Parties</font><font style="display:inline;">&#x201D;.</font>
 </p>
 <p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <a name="AccreditedInvestor"></a><a name="Recitals"></a><font style="display:inline;">Recitals</font>
 </p>
 <p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-weight:bold;">WHEREAS</font><font style="display:inline;">, the Parties desire to transfer ImmunoGen&#x2019;s anti-CD37 antibody-drug conjugate program (the &#x201C;</font><font style="display:inline;font-weight:bold;">Program</font><font style="display:inline;">&#x201D;) to Debiopharm on the terms and subject to the conditions set forth in this <a name="_9kMIH5YVt3AB7AIR7vuirsuA"></a><a name="_9kMIH5YVt39A7AJS7vuirsuA"></a>Agreement.</font>
 </p>
 <p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-weight:bold;">NOW, THEREFORE</font><font style="display:inline;">, in consideration of the mutual representations, warranties and <a name="_9kMHG5YVt4667GMP7vuirsuA"></a>agreements &nbsp;contained in this <a name="_9kMJI5YVt3AB7AIR7vuirsuA"></a><a name="_9kMJI5YVt39A7AJS7vuirsuA"></a>Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the <a name="_9kMHG5YVt466898YGp9H"></a><a name="_9kMHE6YUv4668DJfGp9H"></a>parties agree as follows:</font>
 </p>
 <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
 <p style="text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;width:100%">
 <font style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:normal;text-transform:none;color:#000000;font-size:11pt;text-decoration:none;text-align:center;text-justify:inter-ideograph